NEW YORK (GenomeWeb) — Israeli molecular diagnostics firm Nucleix announced today that it has won a €2.5 million ($2.9 million) Horizon 2020 grant from the European Commission to continue development of its lung cancer screening test.
The test, called Lung EpiCheck, uses changes in DNA methylation patterns in blood samples for the early detection of lung cancer. It is based on the same technology as the firm’s recently CE-marked Bladder EpiCheck urine test for bladder cancer monitoring.
With the new funding, Nucleix said it expects to move Lung EpiCheck into US and European clinical trials around the beginning of 2019.
The company, which won a €50,000 Horizon 2020 grant for its EpiCheck technology in 2016, is also developing cirrhosis and pan-cancer diagnostics.